Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3355
Name fibrosarcoma
Definition A connective tissue cancer that has_material_basis_in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.
Source DiseaseOntology.org
Alt Ids DOID:3509 DOID:156
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer fibrosarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 wild-type Pegylated liposomal doxorubicin + RO6839921 fibrosarcoma sensitive detail...
IDH1 R132C Vorasidenib fibrosarcoma predicted - sensitive detail...
IDH1 R132C Ceralasertib + Olaparib fibrosarcoma sensitive detail...
ALK R401* Crizotinib fibrosarcoma predicted - sensitive detail...
ALK V757M Crizotinib fibrosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed USA 0
NCT01981551 Phase II Nirogacestat Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis Completed USA 0
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting ITA | FRA | ESP 0
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Completed USA 0
NCT02923778 Phase II Talimogene laherparepvec Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Active, not recruiting USA | CAN 0
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Completed USA 0
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Active, not recruiting USA | ITA | CAN | AUS 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU | CHE 1
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting USA 0
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT05809830 Phase Ib/II Doxorubicin Doxorubicin + LB-100 Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) Recruiting ESP 0
NCT05879185 Phase II Izuralimab A Study of XmAb23104 in People With Sarcoma Terminated USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0